Neurobiological Technologies has received a second payment of $2.25million from Merz + Co for achieving goals relating to the neuroprotective agent memantine, currently in a Phase III trial for the treatment of Alzheimer's disease, neuropathic pain and AIDS-related dementia. The payment follows previous sums received by Merz under licensing deals between the company and Forest Laboratories and A/S Lundbeck for memantine (Marketletter August 21, 2000). Neurobiological says that this second payment indicates it is one step closer to the successful launch of memantine.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze